Compare Sezzle Inc (SEZL) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Tango Therapeutics Inc. — how do they compare? Sezzle Inc trades at $122.66 (market cap $4.39B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Sezzle Inc is the larger of the two by market cap, and Sezzle Inc is more actively traded (424,843 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and Tango Therapeutics Inc. for 0 Days on average.
| SEZL | TNGX | |
|---|---|---|
Market Cap | $4.39B | $3.75B |
Volume | 424,843 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $188.55 | $32.90 |
52-Week Low | $50.97 | $7.50 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $4.44B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sezzle (SEZL) trades at $130.05, down 0.33% today, with a bullish technical signal and strong support near $127. The company demonstrates robust fundamentals, with Q2 2026 revenue growth of 51.7% year-over-year and a net income margin of 30.35%. Recent product launches like Sezzle Send and SezzleCash are driving user growth, while analyst consensus remains positive with a $168 price target.
Outlook is favorable given sustained earnings beats and raised guidance, but risks include competitive pressures in the BNPL sector and elevated valuation multiples. The stock offers growth potential if execution continues, though overbought technical indicators suggest near-term volatility.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
